SAN DIEGO, April 15, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune today announced that preclinical studies evaluating lead drug candidate retaspimycin hydrochloride (“retaspimycin,” also known as IPI-504), suggest that retaspimycin represents a novel strategy for the potential treatment of patients with non-small cell lung cancer (NSCLC) who exhibit resistance to Iressa(r) (gefitinib) or Tarceva(r) (erlotinib). Data were presented today during the Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California. Retaspimycin, a selective small molecule inhibitor of heat shock protein 90 (Hsp90), is currently being evaluated in the Phase 2 portion of an ongoing Phase 1/2 clinical trial in patients with advanced non-small cell lung cancer.
